"uveitis; corticosteorids; immunosuppression; cost effectivness"@en . "21460" . "Authors compared clinical and economic effeciency of treatment of the classical corticosteroids therapy and modern immunosuppressive treatment or their combination. Retrospective evaluation carried out in 2012, covering 2006\u20132011, monitored sample of 27 patients, 16 women and 11 men, 45 eyes with disabilities. The average age in the last year of follow-up monitoring was 30.2, ranging from 14 to 76 years. The mean duration of disease for the whole sample is 16.5 years with a range from 6 to 36 years. Three basic diagnoses were included in investigated group: chronic iridocyclitis in 59 % of eyes, intermediate uveitis in 30 % of eyes and sympathetic ophthalmia in 11 % of eyes. The optimal treatment could not be determined accurately. It must be decided depending upon their own forms of uveitis diagnosis. Combined corticosteroid sparing therapy was the most beneficial to maintain in terms of visual acuity with minimal side effects and cost effectiveness. Successful outcomes of treatment were observed for intermediate uveitis, because the visual acuity improved in nine letetters of ETDRS chart in the study. Satisfactory treatment was proved in chronic iridocyclitis and sympathetic ophthalmia in general, because visual acuity improved in a few letters of ETDRS chart, in the same line as in the beginning of the six-year follow-up. Rounded average annual prize for treatment including pharmacotherapy, outpatient and inpatient care and laboratory follow- up was in chronic iridocyclitis @ 990, in intermediate uveitis @ 310 and sympathetic ophthalmia @ 1550. Pharmacotherapy exceeded the financial appraisal of specialized medical and inpatient care in total cost."@en . . "1211-9059" . "Hodnocen\u00ED efektivity l\u00E9\u010Dby neinfek\u010Dn\u00EDch uveitid"@cs . "Hodnocen\u00ED efektivity l\u00E9\u010Dby neinfek\u010Dn\u00EDch uveitid" . "7"^^ . "Hodnocen\u00ED efektivnosti l\u00E9\u010Dby neinfek\u010Dn\u00EDch uveitid. Auto\u0159ii porovnali klinickou a ekonomickou efektivitu l\u00E9\u010Dby tohoto onemocn\u011Bn\u00ED klasickou terapi\u00ED kortikosteroidy a modern\u00ED l\u00E9\u010Dbou imunosupresivn\u00EDmi prepar\u00E1ty \u010Di jejich kombinac\u00ED. Retrospektivn\u00ED hodnocen\u00ED proveden\u00E9 v roce 2012 se t\u00FDkalo p\u0159edchoz\u00EDch \u0161esti let (2006\u20132011) u sledovan\u00E9ho souboru 27 pacient\u016F, a to 16 \u017Een a 11 mu\u017E\u016F, s posti\u017Een\u00EDm 45 o\u010D\u00ED. Pr\u016Fm\u011Brn\u00FD v\u011Bk v posledn\u00EDm roce sledov\u00E1n\u00ED \u010Dinil 30,2 roku, s rozp\u011Bt\u00EDm od 14 do 76 let. Pr\u016Fm\u011Brn\u00E1 d\u00E9lka trv\u00E1n\u00ED choroby pro cel\u00FD soubor je 16,5 roku s rozp\u011Bt\u00EDm 6 a\u017E 36 let. Sledovan\u00FD soubor zahrnoval t\u0159i z\u00E1kladn\u00ED diagn\u00F3zy: chronickou iridocyklitidu na 59 % o\u010D\u00ED, intermedi\u00E1ln\u00ED uveitidu na 30 % o\u010D\u00ED a sympatickou oftalmii na 11 % o\u010D\u00ED. Optim\u00E1ln\u00ED variantu l\u00E9\u010Dby nebylo mo\u017Eno p\u0159esn\u011B stanovit, av\u0161ak kombinovan\u00E1 kortikosteroidy \u0161et\u0159\u00EDc\u00ED l\u00E9\u010Dba byla z hlediska udr\u017Een\u00ED zrakov\u00E9 ostrosti s minimalizac\u00ED ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F a n\u00E1kladov\u00E9 n\u00E1ro\u010Dnosti nejp\u0159\u00EDnosn\u011Bj\u0161\u00ED. \u00DAsp\u011B\u0161n\u00E9 v\u00FDsledky l\u00E9\u010Dby byly zaznamen\u00E1ny u intermedi\u00E1ln\u00ED uveitidy, nebo\u0165 zrakov\u00E1 ostrost v pr\u016Fb\u011Bhu studie se zlep\u0161ila o 9 p\u00EDsmen ETDRS. Uspokojiv\u00E1 l\u00E9\u010Dba byla prok\u00E1z\u00E1na celkov\u011B u chronick\u00E9 iridocyklitidy i soucitn\u00E9ho onemocn\u011Bn\u00ED, nebo\u0165 v\u00EDzus se zlep\u0161il o n\u011Bkolik p\u00EDsmen na \u00FArovni stejn\u00E9ho \u0159\u00E1dku ETDRS jako na za\u010D\u00E1tku \u0161estilet\u00E9ho sledov\u00E1n\u00ED. Pr\u016Fm\u011Brn\u00E1 ro\u010Dn\u00ED cena (zaokrouhlen\u00E1) za o\u0161et\u0159en\u00ED zahrnuj\u00EDc\u00ED farmakoterapii, ambulantn\u00ED a hospitaliza\u010Dn\u00ED p\u00E9\u010Di a laboratorn\u00ED sledov\u00E1n\u00ED \u010Dinila u chronick\u00E9 iridocyklitidy 24 700 K\u010D, u intermedi\u00E1ln\u00ED uveitidy 7700 K\u010D a u sympatick\u00E9 oftalmie 38 500 K\u010D. Farmakoterapie v celkov\u00FDch n\u00E1kladech p\u0159evy\u0161ovala odbornou p\u00E9\u010Di l\u00E9ka\u0159\u016F v\u010Detn\u011B hospitalizac\u00ED."@cs . . . . "I" . . "Hodnocen\u00ED efektivity l\u00E9\u010Dby neinfek\u010Dn\u00EDch uveitid"@cs . "Ceska a Slovenska Oftalmologie" . "Kr\u00E1sn\u00FD, J." . "RIV/68407700:21460/13:00209478!RIV14-MSM-21460___" . "CZ - \u010Cesk\u00E1 republika" . "77700" . "Kr\u00E1sn\u00E1, Jana" . . . . "[7B281E8E0A65]" . . "Hodnocen\u00ED efektivnosti l\u00E9\u010Dby neinfek\u010Dn\u00EDch uveitid. Auto\u0159ii porovnali klinickou a ekonomickou efektivitu l\u00E9\u010Dby tohoto onemocn\u011Bn\u00ED klasickou terapi\u00ED kortikosteroidy a modern\u00ED l\u00E9\u010Dbou imunosupresivn\u00EDmi prepar\u00E1ty \u010Di jejich kombinac\u00ED. Retrospektivn\u00ED hodnocen\u00ED proveden\u00E9 v roce 2012 se t\u00FDkalo p\u0159edchoz\u00EDch \u0161esti let (2006\u20132011) u sledovan\u00E9ho souboru 27 pacient\u016F, a to 16 \u017Een a 11 mu\u017E\u016F, s posti\u017Een\u00EDm 45 o\u010D\u00ED. Pr\u016Fm\u011Brn\u00FD v\u011Bk v posledn\u00EDm roce sledov\u00E1n\u00ED \u010Dinil 30,2 roku, s rozp\u011Bt\u00EDm od 14 do 76 let. Pr\u016Fm\u011Brn\u00E1 d\u00E9lka trv\u00E1n\u00ED choroby pro cel\u00FD soubor je 16,5 roku s rozp\u011Bt\u00EDm 6 a\u017E 36 let. Sledovan\u00FD soubor zahrnoval t\u0159i z\u00E1kladn\u00ED diagn\u00F3zy: chronickou iridocyklitidu na 59 % o\u010D\u00ED, intermedi\u00E1ln\u00ED uveitidu na 30 % o\u010D\u00ED a sympatickou oftalmii na 11 % o\u010D\u00ED. Optim\u00E1ln\u00ED variantu l\u00E9\u010Dby nebylo mo\u017Eno p\u0159esn\u011B stanovit, av\u0161ak kombinovan\u00E1 kortikosteroidy \u0161et\u0159\u00EDc\u00ED l\u00E9\u010Dba byla z hlediska udr\u017Een\u00ED zrakov\u00E9 ostrosti s minimalizac\u00ED ne\u017E\u00E1douc\u00EDch \u00FA\u010Dink\u016F a n\u00E1kladov\u00E9 n\u00E1ro\u010Dnosti nejp\u0159\u00EDnosn\u011Bj\u0161\u00ED. \u00DAsp\u011B\u0161n\u00E9 v\u00FDsledky l\u00E9\u010Dby byly zaznamen\u00E1ny u intermedi\u00E1ln\u00ED uveitidy, nebo\u0165 zrakov\u00E1 ostrost v pr\u016Fb\u011Bhu studie se zlep\u0161ila o 9 p\u00EDsmen ETDRS. Uspokojiv\u00E1 l\u00E9\u010Dba byla prok\u00E1z\u00E1na celkov\u011B u chronick\u00E9 iridocyklitidy i soucitn\u00E9ho onemocn\u011Bn\u00ED, nebo\u0165 v\u00EDzus se zlep\u0161il o n\u011Bkolik p\u00EDsmen na \u00FArovni stejn\u00E9ho \u0159\u00E1dku ETDRS jako na za\u010D\u00E1tku \u0161estilet\u00E9ho sledov\u00E1n\u00ED. Pr\u016Fm\u011Brn\u00E1 ro\u010Dn\u00ED cena (zaokrouhlen\u00E1) za o\u0161et\u0159en\u00ED zahrnuj\u00EDc\u00ED farmakoterapii, ambulantn\u00ED a hospitaliza\u010Dn\u00ED p\u00E9\u010Di a laboratorn\u00ED sledov\u00E1n\u00ED \u010Dinila u chronick\u00E9 iridocyklitidy 24 700 K\u010D, u intermedi\u00E1ln\u00ED uveitidy 7700 K\u010D a u sympatick\u00E9 oftalmie 38 500 K\u010D. Farmakoterapie v celkov\u00FDch n\u00E1kladech p\u0159evy\u0161ovala odbornou p\u00E9\u010Di l\u00E9ka\u0159\u016F v\u010Detn\u011B hospitalizac\u00ED." . "Efficiency Evaluation of Non-infectious Uveitis"@en . . "Mezerov\u00E1, Veronika" . "RIV/68407700:21460/13:00209478" . . "2"^^ . "3"^^ . . . "2" . . . "Hodnocen\u00ED efektivity l\u00E9\u010Dby neinfek\u010Dn\u00EDch uveitid" . . . "Efficiency Evaluation of Non-infectious Uveitis"@en .